FTC Wants Closer Look At $25B Actavis-Forest Labs Deal
The Federal Trade Commission is seeking more details on generic-drug maker Actavis PLC's proposed $25 billion acquisition of Forest Laboratories Inc., the companies said Thursday, adding scrutiny to a deal that...To view the full article, register now.
Already a subscriber? Click here to view full article